meta
|
Preg
- medecines during pregnancy KB
Search
Duloxetine
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Paternal exp. genotoxic window only (0–3 months preconception)
Paternal exposure: epigenetic window only (3–xxx months preconception)
Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception)
Paternal exposure: other window
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)
Källen, 2013 Ozturk, 2016 Anderson, 2020 Bahat, 2020 Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
6
1.03
[
0.84
; 1.27]
31,093
4,405
not evaluable
Major congenital malformations
Källen, 2013 Ozturk, 2016 Anderson, 2020 Bahat, 2020 Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
6
1.03
[
0.84
; 1.27]
31,093
4,405
not evaluable
Congenital heart defects
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
1.32
[
0.94
; 1.85]
162
3,976
not evaluable
Abdominal wall defects
Huybrechts (Controls unexposed, sick), 2020
1
0.45
[
0.21
; 0.96]
-
2,532
not evaluable
Digestive system anomalies
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
1.06
[
0.45
; 2.49]
39
3,966
not evaluable
Eye defects
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
0.67
[
0.24
; 1.91]
13
3,966
not evaluable
Genital anomalies
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
1.10
[
0.56
; 2.19]
13
3,966
not evaluable
Limb defects
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
0.54
[
0.33
; 0.89]
56
3,966
not evaluable
Nervous system anomalies
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
0.88
[
0.31
; 2.53]
-
3,966
not evaluable
Oro-facial clefts
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
1.16
[
0.31
; 4.31]
-
3,966
not evaluable
Respiratory system anomalies
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
1.03
[
0.40
; 2.67]
-
3,966
not evaluable
Urinary malformations
Huybrechts (Controls unexposed, sick), 2020 Ankarfeldt a (Controls unexposed, sick), 2021
2
1.18
[
0.64
; 2.18]
14
3,966
not evaluable
Ear malformations
0
-
-
-
-
-
Ear, face and neck anomalies
Ankarfeldt a (Controls unexposed, sick), 2021
1
6.00
[
0.72
; 49.92]
-
1,434
not evaluable
Minor congenital malformations
Ankarfeldt a (Controls unexposed, sick), 2021
1
1.24
[
0.89
; 1.73]
157
1,444
not evaluable
Other anomalies/syndromes (non chromosomal)
Ankarfeldt a (Controls unexposed, sick), 2021
1
1.75
[
0.73
; 4.18]
22
1,434
not evaluable
Other congenital malformations (Q80 to Q99)
Huybrechts (Controls unexposed, sick), 2020
1
1.33
[
0.41
; 4.30]
-
2,532
not evaluable
Growth parameters and prematurity
Preterm (< 37 weeks)
Ozturk, 2016 Bahat, 2020 Huybrechts (Controls unexposed, NOS), 2020 Marks (Controls exposed to Bupropion), 2021 Ankarfeldt (Controls unexposed, sick), 2023 Martin - UK, 2024 Martin - Norway, 2024
7
1.82
[
1.32
; 2.51]
201,709
1,658
serious
Small for gestational age (weight)
Huybrechts (Controls unexposed, NOS), 2020 Ankarfeldt (Controls unexposed, sick), 2023 Martin - Norway, 2024 Martin - UK, 2024
4
1.01
[
0.76
; 1.36]
116,759
1,487
not evaluable
Maternal consequences
Preeclampsia
Palmsten, 2013 Huybrechts (Controls unexposed, NOS), 2020
2
1.11
[
0.95
; 1.29]
51,976
3,059
not evaluable
Postpartum hemorrhage
Huybrechts (Controls unexposed, NOS), 2020
1
1.53
[
1.08
; 2.17]
96,022
955
not evaluable
Neonatal disorders
Low Apgar score (< 7) (at 5 min)
Marks (Controls exposed to Bupropion), 2021 Martin, 2024
2
1.59
[
1.21
; 2.08]
31,112
1,656
not evaluable
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation
Marks (Controls unexposed, sick), 2021
1
4.76
[
2.28
; 9.95]
-
59
not evaluable
Jaundice / Icterus
Marks (Controls exposed to Bupropion), 2021
1
0.97
[
0.57
; 1.66]
84
139
not evaluable
Neonatal medical care
Marks (Controls exposed to Bupropion), 2021
1
2.04
[
1.29
; 3.23]
146
139
not evaluable
Neonatal tachypnea
Marks (Controls exposed to Bupropion), 2021
1
1.89
[
1.06
; 3.37]
56
139
not evaluable
Persistent pulmonary hypertension
Marks (Controls exposed to Bupropion), 2021
1
8.85
[
0.36
; 218.46]
1
139
not evaluable
Intrauterine deaths
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions
Kjaersgaard (Controls unexposed, sick), 2013 Ozturk, 2016 Ankarfeldt b (Controls unexposed, sick), 2021
3
1.79
[
0.68
; 4.71]
321
1,200
not evaluable
Elective/induced termination of pregnancy
Ozturk, 2016 Ankarfeldt b (Controls unexposed, sick), 2021
2
1.41
[
1.21
; 1.64]
733
1,200
not evaluable
Late intrauterine deaths (> 22 weeks) / Stillbirths
Ankarfeldt a (Controls unexposed, sick), 2021
1
0.83
[
0.25
; 2.74]
11
1,559
not evaluable
0.2
100.0
1.0
